Amgen Inc. (AMGN) To Go Ex-Dividend on May 15th

Amgen Inc. (NASDAQ:AMGN) announced a quarterly dividend on Wednesday, March 4th. Shareholders of record on Friday, May 15th will be paid a dividend of 2.52 per share by the medical research company on Friday, June 5th. This represents a c) dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Friday, May 15th.

Amgen has increased its dividend payment by an average of 0.1%per year over the last three years and has raised its dividend every year for the last 14 years. Amgen has a payout ratio of 46.8% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Amgen to earn $21.39 per share next year, which means the company should continue to be able to cover its $10.08 annual dividend with an expected future payout ratio of 47.1%.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $367.60 on Friday. The company has a market capitalization of $198.16 billion, a PE ratio of 25.83, a PEG ratio of 3.76 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock’s 50 day moving average price is $352.53 and its 200-day moving average price is $321.90. Amgen has a twelve month low of $261.43 and a twelve month high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts anticipate that Amgen will post 20.62 EPS for the current year.

Institutional Investors Weigh In On Amgen

Several institutional investors and hedge funds have recently made changes to their positions in AMGN. Dogwood Wealth Management LLC raised its stake in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares during the last quarter. Anfield Capital Management LLC boosted its holdings in shares of Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the last quarter. Board of the Pension Protection Fund bought a new stake in shares of Amgen during the 4th quarter valued at $26,000. Legacy Investment Solutions LLC purchased a new stake in Amgen in the second quarter worth about $27,000. Finally, Manning & Napier Advisors LLC increased its holdings in Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.